Nucleostemin and ASPP2 expression is correlated with pituitary adenoma proliferation

Ma,Lin; Chen,Zhi‑Min; Li,Xue‑Yuan; Wang,Xin‑Jun; Shou,Ji‑Xin; Fu,Xu‑Dong

doi:10.3892/ol.2013.1562

Nucleostemin and ASPP2 expression is correlated with pituitary adenoma proliferation

Authors:
- Lin Ma
- Zhi‑Min Chen
- Xue‑Yuan Li
- Xin‑Jun Wang
- Ji‑Xin Shou
- Xu‑Dong Fu
View Affiliations

Affiliations: Department of Neurosurgery, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: September 4, 2013 https://doi.org/10.3892/ol.2013.1562
Pages: 1313-1318

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nucleostemin is a GTP‑conjugated protein located in the nucleoli of stem cells and certain cancer cells, and maintains cellular self‑renewal. The present study aimed to evaluate nucleostemin as a potential target for pituitary adenoma gene therapy by investigating nucleostemin and apoptosis‑stimulating of p53 protein 2 (ASPP2) expression and their effect on pituitary adenoma cell proliferation. A total of 71 samples of pituitary adenomas were collected. Semi‑quantitative PCR was used to detect the expression of nucleostemin and ASPP2 mRNA in the samples. Immunochemistry techniques were used to examine Ki‑67 expression in the paraffin section of the samples. Coherent clinical data were also collected. Nucleostemin and ASPP2 were detectable in all the pituitary adenoma samples. Significant differences were observed in nucleostemin and ASPP2 expression between invasive pituitary adenoma and non‑invasive pituitary adenomas (P<0.01) and the Ki‑67 labeling index (LI; P>0.05). The difference in the Ki‑67 LI between the recurrence and non‑recurrence groups was significant (P<0.05). There was positive correlation between nucleostemin gene expression and the Ki‑67 LI levels (P<0.05). The correlation between ASPP2 expression and the Ki‑67 LI was negative (P<0.05). Negative correlation was demonstrated between nucleostemin and ASPP2 expression (P<0.01). The nucleostemin and ASPP2 genes were expressed in the human pituitary adenoma tissues. The differences in the expression of nucleostemin, ASPP2 and Ki‑67 in the various pathological types of pituitary adenomas represented differences in molecular biological character and were associated with invasion. In the pituitary adenomas, the expression of nucleostemin and ASPP2 was correlated with tumor proliferation. Nucleostemin, ASPP2 and Ki‑67 may serve as valid clinical detection markers for the invasion of pituitary adenomas.

View Figures

View References

1	Kepes JJ, Chen WY, Pang LC and Kepes M: Tumors of the central nervous system in Taiwan, Republic of China. Surg Neurol. 22:149–156. 1984. View Article : Google Scholar : PubMed/NCBI
2	Tsai RY and McKay RD: A nucleolar mechanism controlling cell proliferation in stem cells and cancer cells. Genes Dev. 16:2991–3003. 2002. View Article : Google Scholar : PubMed/NCBI
3	Riddihough G and Pennisi E: The evolution of epigenetics. Science. 293:10632001. View Article : Google Scholar : PubMed/NCBI
4	Samuels-Lev Y, O’Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S, Campargue I, Naumovski L, Crook T and Lu X: ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell. 8:781–794. 2001. View Article : Google Scholar : PubMed/NCBI
5	Mampalam TJ, Tyrrell JB and Wilson CB: Transsphenoidal microsurgery for Cushing disease. A report of 216 cases. Ann Intern Med. 109:487–493. 1988. View Article : Google Scholar : PubMed/NCBI
6	Qu J and Bishop JM: Nucleostemin maintains self-renewal of embryonic stem cells and promotes reprogramming of somatic cells to pluripotency. J Cell Biol. 197:731–745. 2012. View Article : Google Scholar : PubMed/NCBI
7	Tsai RY and McKay RD: A multistep, GTP-driven mechanism controlling the dynamic cycling of nucleostemin. J Cell Biol. 168:179–184. 2005. View Article : Google Scholar : PubMed/NCBI
8	Sijin L, Ziwei C, Yajun L, Meiyu D, Hongwei Z, Guofa H, Siguo L, Hong G, Zhihong Z, Xiaolei L, Yingyun W, Yan X and Weide L: The effect of knocking-down nucleostemin gene expression on the in vitro proliferation and in vivo tumorigenesis of HeLa cells. J Exp Clin Cancer Res. 23:529–538. 2004.PubMed/NCBI
9	Bergamaschi D, Samuels Y, O’Neil NJ, Trigiante G, Crook T, Hsieh JK, O’Connor DJ, Zhong S, Campargue I, Tomlinson ML, Kuwabara PE and Lu X: iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet. 33:162–167. 2003. View Article : Google Scholar : PubMed/NCBI
10	Llanos S, Royer C, Lu M, Bergamaschi D, Lee WH and Lu X: Inhibitory member of the apoptosis-stimulating proteins of the p53 family (iASPP) interacts with protein phosphatase 1 via a noncanonical binding motif. J Biol Chem. 286:43039–43044. 2011. View Article : Google Scholar
11	Lossos IS, Natkunam Y, Levy R and Lopez CD: Apoptosis stimulating protein of p53 (ASPP2) expression differs in diffuse large B-cell and follicular center lymphoma: correlation with clinical outcome. Leuk Lymphoma. 43:2309–2317. 2002. View Article : Google Scholar
12	Zhu Z, Ramos J, Kampa K, Adimoolam S, Sirisawad M, Yu Z, Chen D, Naumovski L and Lopez CD: Control of ASPP2/(53BP2L) protein levels by proteasomal degradation modulates p53 apoptotic function. J Biol Chem. 280:34473–34480. 2005. View Article : Google Scholar : PubMed/NCBI
13	Bergamaschi D, Samuels Y, Zhong S and Lu X: Mdm2 and mdmX prevent ASPP1 and ASPP2 from stimulating p53 without targeting p53 for degradation. Oncogene. 24:3836–3841. 2005. View Article : Google Scholar : PubMed/NCBI
14	Wang Y, Godin-Heymann N, Dan Wang X, Bergamaschi D, Llanos S and Lu X: ASPP1 and ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer cells. Cell Death Differ. 20:525–534. 2013. View Article : Google Scholar : PubMed/NCBI
15	Wolfsberger S, Kitz K, Wunderer J, Czech T, Boecher-Schwarz HG, Hainfellner JA and Knosp E: Multiregional sampling reveals a homogenous distribution of Ki-67 proliferation rate in pituitary adenomas. Acta Neurochir (Wien). 146:1323–1328. 2004. View Article : Google Scholar : PubMed/NCBI
16	Honegger J, Prettin C, Feuerhake F, Petrick M, Schulte-Mönting J and Reincke M: Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. J Neurosurg. 99:674–679. 2003. View Article : Google Scholar : PubMed/NCBI
17	Liu X, Ma S, Yao Y, Li G, Feng M, Deng K, Dai C, Cai F, Li Y, Zhang B and Wang R: Differential expression of folate receptor alpha in pituitary adenomas and its relationship to tumor behavior. Neurosurgery. 70:1274–1280. 2012. View Article : Google Scholar : PubMed/NCBI
18	Saeger W, Lüdecke B and Lüdecke DK: Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas. Exp Clin Endocrinol Diabetes. 116:80–85. 2008. View Article : Google Scholar : PubMed/NCBI
19	Rishi A, Sharma MC, Sarkar C, Jain D, Singh M, Mahapatra AK, Mehta VS and Das TK: A clinicopathological and immunohistochemical study of clinically non-functioning pituitary adenomas: a single institutional experience. Neurol India. 58:418–423. 2010. View Article : Google Scholar : PubMed/NCBI
20	Wolfsberger S, Wunderer J, Zachenhofer I, Czech T, Böcher-Schwarz HG, Hainfellner J and Knosp E: Expression of cell proliferation markers in pituitary adenomas - correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha. Acta Neurochir (Wien). 146:831–839. 2004. View Article : Google Scholar : PubMed/NCBI
21	Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V and Laws ER Jr: Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg. 114:336–344. 2011. View Article : Google Scholar : PubMed/NCBI